High-level expression of BCL3 differentiates t(2;5)(p23;q35)-positive anaplastic large cell lymphoma from Hodgkin disease

Blood

Volumn 101, Issue 7, 2003, Pages 2789-2796

  Nishikori, Momoko ^b   Maesako, Yoshitomo ^b   Ueda, Chiyoko ^b   Kurata, Masayuki ^b   Uchiyama, Takashi ^b   Ohno, Hitoshi ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; NUCLEAR PROTEIN; PROTEIN BCL 3; PROTEIN INHIBITOR; PROTEIN P50; RNA DIRECTED DNA POLYMERASE; TRANSCRIPTION FACTOR; ONCOPROTEIN; PROTO ONCOGENE PROTEIN BCL 3; PROTO-ONCOGENE PROTEIN BCL-3;

ARTICLE; B CELL LEUKEMIA; BCL3 GENE; BINDING AFFINITY; CELL LINE; CHROMOSOME TRANSLOCATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DIFFERENTIAL DIAGNOSIS; FLUORESCENCE; GEL MOBILITY SHIFT ASSAY; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE LOCUS; GENETIC CODE; HODGKIN DISEASE; HUMAN; HUMAN CELL; IN SITU HYBRIDIZATION; LARGE CELL LYMPHOMA; MEASUREMENT; NORTHERN BLOTTING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; WESTERN BLOTTING; CELL CULTURE; CHROMOSOME 2; CHROMOSOME 5; DIMERIZATION; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE TRANSLOCATION; GENETICS; METABOLISM;

CHROMOSOMES, HUMAN, PAIR 2; CHROMOSOMES, HUMAN, PAIR 5; CPG ISLANDS; DIAGNOSIS, DIFFERENTIAL; DIMERIZATION; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION PROFILING; HODGKIN DISEASE; HUMANS; LYMPHOMA, LARGE-CELL, KI-1; PROTO-ONCOGENE PROTEINS; RNA, MESSENGER; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0038107396     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-08-2464     Document Type: Article

References (50)

1. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66:848-858.
2. + anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96:3681-3695.
3. - lymphomas: a distinct molecular genetic subtype of non-Hodgkin's lymphoma. Br J Haematol. 2001;113:275-295.
4. Falini B, Bigerna B, Fizzotti M, et al. ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. Am J Pathol. 1998;153:875-886.
5. Benharroch D, Meguerian-Bedoyan Z, Lamant L, et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood. 1998;91:2076-2084.
6. Drexler HG, Gignac SM, von Wasielewski R, Werner M, Dirks WG. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia. 2000;14:1533-1559.
7. Bai R-Y, Dieter P, Peschel C, Morris SW, Duyster J. Nucreophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-γ to mediate its mitogenicity. Mol Cell Biol. 1998;18:6951-6961.
8. Bai R-Y, Ouyang T, Miething C, Morris SW, Peschel C, Duyster J. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood. 2000;96:4319-4327.
9. Duyster J, Bai R-Y, Morris SW. Translocations involving anaplastic lymphoma kinase (ALK). Oncogene. 2001;20:5623-5637.
10. Falini B, Pileri S, Pizzolo G, et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 1995;85:1-14.
11. Staudt LM. The molecular and cellular origins of Hodgkin's disease. J Exp Med. 2000;191:207-212.
12. Bargou RC, Leng C, Krappmann D, et al. High-level nuclear NF-κB and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood. 1996;87:4340-4347.
13. Emmerich F, Meiser M, Hummel M, et al. Overexpression of I κ B α without inhibition of NF-κB activity and mutations in the I κ B α gene in Reed-Sternberg cells. Blood. 1999;94:3129-3134.
14. Cabannes E, Khan G, Aillet F, Jarrett RF, Hay RT. Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for hκBα. Oncogene. 1999;18:3063-3070.
15. Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B, Scheidereit C. Molecular mechanisms of constitutive NF-κB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene. 1999;18:943-953.
16. Jungnickel B, Staratschek-Jox A, Brauninger A, et al. Clonal deleterious mutations in the IκBα gene in the malignant cells in Hodgkin's lymphoma. J Exp Med. 2000;191:395-401.
17. Gruss H-J, DaSilva N, Hu Z-B, Uphoff CC, Goodwin RG, Drexler HG. Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines. Leukemia. 1994;8:2083-2094.
18. Gruss H-J, Boiani N, Williams DE, Armitage RJ, Smith CA, Goodwin RG. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood. 1994;83:2045-2056.
19. Masuda M, Ishida C, Arai Y, et al. Dual action of CD30 antigen: anti-CD30 antibody induced apoptosis and interleukin-8 secretion in Ki-1 lymphoma cells. Int J Hematol. 1998;67:257-265.
20. Mir SS, Richter BWM, Duckett CS. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood. 2000;96:4307-4312.
21. Franzoso G, Bours V, Park S, Tomita-Yamaguchi M, Kelly K, Siebenlist U. The candidate oncoprotein Bcl-3 is an antagonist of p50/NF-κB-mediated inhibition. Nature. 1992;359:339-342.
22. Wulczyn FG, Naumann M, Scheidereit C. Candidate proto-oncogene bcl-3 encodes a subunit-specific inhibitor of transcription factor NF-κB. Nature. 1992;358:597-599.
23. Franzoso G, Bours V, Azarenko V, et al. The oncoprotein Bcl-3 can facilitate NF-κB-mediated transactivation by removing inhibiting p50 homodimers from select κB sites. EMBO J. 1993;12:3893-3901.
24. Bours V, Franzoso G, Azarenko V, et al. The oncoprotein Bcl-3 directly transactivates through KB motifs via association with DNA-binding p50B homodimers. Cell. 1993;72:729-739.
25. Fujita T, Nolan GP, Liou H-C, Scott ML, Baltimore D. The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-κB p50 homodimers. Genes Dev. 1993;7:1354-1363.
26. Naumann M, Wulczyn FG, Scheidereit C. The NF-κB precursor p105 and the proto-oncogene product Bcl-3 are κB molecules and control nuclear translocation of NF-κB. EMBO J. 1993;12:213-222.
27. Nolan GP, Fujita T, Bhatia K, et al. The bcl-3 proto-oncogene encodes a nuclear IκB-like molecule that preferentially interacts with NF-κB p50 and p52 in a phosphorylation-dependent manner. Mol Cell Biol. 1993;13:3557-3566.
28. Zhang Q, Didonato JA, Karin M, McKeithan TW. BCL3 encodes a nuclear protein which can alter the subcellular location of NF-λB proteins. Mol Cell Biol. 1994;14:3915-3926.
29. Watanabe N, Iwamura T, Shinoda T, Fujita T. Regulation of NFKB1 proteins by the candidate oncoprotein BCL-3: generation of NF-κB homodimers from the cytoplasmic pool of p50-p105 and nuclear translocation. EMBO J. 1997;16:3609-3620.
30. McKeiihan TW, Ohno H, Dickstein J, Hume E. Genomic structure of the candidate protooncogene BCL3. Genomics. 1994;24:120-126.
31. Ohno H, Takimoto G, McKeithan TW. The candidate proto-oncogene bcl-3 is related to genes implicated in cell lineage determination and cell cycle control. Cell. 1990;60:991-997.
32. Ohno H, Doi S, Yabumoto K, Fukuhara S, McKeithan TW. Molecular characterization of the t(14;19)(q32;q13) translocation in chronic lymphocytic leukemia. Leukemia. 1993;7:2057-2063.
33. McKeithan TW, Takimoto GS, Ohno H, et al. BCL3 rearrangements and t(14;19) in chronic lymphocytic leukemia and other B-cell malignancies: a molecular and cytogenetic study. Genes Chromosomes Cancer. 1997;20:64-72.
34. Mitchell TC, Hildeman D, Kedl RM, et al. Immunological adjuvants promote activated T cell survival via induction of Bcl-3. Nat Immunol. 2001;2:397-402.
35. Drexler HG, Matsuo AY, MacLeod RAF. Continuous hematopoietic cell lines as model systems for leukemia-lymphoma research. Leuk Res. 2000;24:881-911.
36. Kamesaki H, Fukuhara S, Tatsumi E, et al. Cytochemical, immunologic, chromosomal, and molecular genetic analysis of a novel cell line derived from Hodgkin's disease. Blood. 1986;68:285-292.
37. Maesako Y, Akasaka T, Uchiyama T, Ohno H. Improved DNA-based polymerase chain reaction amplification of t(2;5)(p23;q35) breakpoints. Int J Hematol. 2000;72:110-111.
38. Akasaka H, Akasaka T, Kurata M, et al. Molecular anatomy of BCL6 translocations revealed by long-distance polymerase chain reaction-based assays. Cancer Res. 2000;60:2335-2341.
39. Ueda C, Akasaka T, Kurata M, et al. The gene for interleukin-21 receptor is the partner of BCL6 in t(3;16)(q27;p11), which is recurrently observed in diffuse large B-cell lymphoma. Oncogene. 2002;21:368-376.
40. Wellmann A, Thieblemont C, Pittaluga S, et al. Detection of differentially expressed genes in lymphomas using cDNA arrays: identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas. Blood. 2000;96:398-404.
41. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999;286:531-537.
42. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511.
43. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8:68-74.
44. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937-1947.
45. Joos S, Menz CK, Wrobel G, et al. Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2. Blood. 2002;99:1381-1387.
46. Ong ST, Hackbarth ML, Degenstein LC, Baunoch DA, Anastasi J, McKeithan TW. Lymphadenopathy, splenomegaly, and altered immunoglobulin production in BCL3 transgenic mice. Oncogene. 1998;16:2333-2343.
47. Gerondakis S, Strasser A. To live and let die. Nat Immunol. 2001;2:377-379.
48. Larsen F, Solheim J, Prydz H. A methylated CpG island 3′ in the apolipoprotein-E gene does not repress its transcription. Hum Mol Genet. 1993;2:775-780.
49. Stoger R, Kubicka P, Liu C-G, et al. Maternal-specific methylation of the imprinted mouse Igf2r locus identifies the expressed locus as carrying the imprinting signal. Cell. 1993;73:61-71.
50. Jung W, Krueger S, Renner C, et al. Opposite effects of the CD30 ligand are not due to CD30 mutations: results from cDNA cloning and sequence comparison of the CD30 antigen from different sources. Mol Immunol. 1994;31:1329-1334.